5 min listen
Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs
FromASCO Education
ratings:
Length:
7 minutes
Released:
Jul 18, 2018
Format:
Podcast episode
Description
Dr. Jonathan Strosberg, section chief of the Neuroendocrine Tumor Division of the Moffitt Cancer Center, discusses the recent FDA approval of Lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Released:
Jul 18, 2018
Format:
Podcast episode
Titles in the series (100)
ASCO Guidelines: Management of Small Renal Masses: ASCO Guidelines: Management of Small Renal Masses by ASCO Education